Advertisement
Opinion
Video
Final Thoughts/Looking Forward
Author(s):
EP: 1.Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
EP: 2.Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
EP: 3.Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
EP: 4.Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
EP: 5.Exciting Data and Trials in Progress from ASCO 2024
EP: 6.Ongoing RCC Clinical Trials that may Impact Practice
EP: 7.Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
EP: 8.Dr Voss Application of Updated KEYNOTE-564 Data
EP: 9.Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
EP: 10.World Health Organization (WHO) Classification Updates for Papillary RCC
EP: 11.Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
EP: 12.The Role of Chemotherapy in nccRCC Treatment
EP: 13.Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
Now Viewing
EP: 14.Final Thoughts/Looking Forward
Related Videos
Related Content
Advertisement
Related Content
Advertisement
Latest Conference Coverage
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
Contact Info
2 Commerce Drive
Cranbury, NJ 08512
